Statistics from Altmetric.com
- Pulmonary embolism
- aspergillus lung disease
- imaging/CT MRI etc
- occupational lung disease
- interstitial fibrosis
- COPD epidemiology
- cystic fibrosis
- lung cancer
- primary pulmonary hypertension
- drug reactions
- innate immunity
We thank Dutt et al1 for their comments on the recent UKLS Position Statement.2 The UKLS Position Statement focused on the recent NLST trial publication in the New England Journal of Medicine3 and was not an overview of all of the primary and secondary outcomes of the pilot UKLS trial. Further details of these outcomes have been given in our first paper on the UKLS trial, which focused on the basic design of the trial including radiology protocol and nodule management.4 All four points raised by Dutt et al are aspects we will study within the screening trial.
The UKLS is specifically designed to select high risk individuals as these are the very group who will benefit the most from such a CT screening trial. Apart from demonstrating a mortality advantage with CT screening, cost effectiveness will be a major issue in determining whether lung cancer screening is considered a feasible option for early lung cancer detection in the UK.
Once CT screening has been demonstrated to be an effective early detection measure within the NHS for high risk individuals, then will be the time to consider modelling for high risk within ethnic communities.5
Competing interests None.
Provenance and peer review Not commissioned; internally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.